<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.deals.v2.DealRecordsOutput xmlns:ns2="local"><serviceExecutionTime>249</serviceExecutionTime><Deal id="107412"><Title>Roche to develop Japan Tobacco's JTT-705 outside Japan and Korea</Title><CompanyPrincipal id="17327">Japan Tobacco Inc</CompanyPrincipal><CompanyPartner id="19446">Roche Holding AG</CompanyPartner><Type>Drug - Development/Commercialization License</Type><Status>Terminated</Status><ValuesToPrincipal><ValuePaid accuracy="Payment Unspecified" max="0.0" min="0.0"></ValuePaid><ValueProjected accuracy="Payment Unspecified" max="0.0" min="0.0"></ValueProjected></ValuesToPrincipal><ValuesToPartner><ValuePaid accuracy="Unknown" max="0.0" min="0.0"></ValuePaid><ValueProjected accuracy="Unknown" max="0.0" min="0.0"></ValueProjected></ValuesToPartner><TerritoriesIncluded><Territory id="WO">World</Territory></TerritoriesIncluded><TerritoriesExcluded><Territory id="JP">Japan</Territory><Territory id="KR">South Korea</Territory></TerritoriesExcluded><PaymentsProjected><PaymentsToPrincipal><Payment><Reference>565434</Reference><Type>Other Milestones</Type><Value accuracy="Payment Unspecified"></Value></Payment><Payment><Reference>565434</Reference><Type>Upfront Payment</Type><Value accuracy="Payment Unspecified"></Value></Payment><Payment><Reference>565434</Reference><Type>Royalty Payment</Type><Value accuracy="Payment Unspecified"></Value></Payment><Payment><Reference>565434</Reference><Type>Other Milestones</Type><Value accuracy="Payment Unspecified"></Value></Payment><Payment><Reference>565434</Reference><Type>Royalty Payment</Type><Value accuracy="Payment Unspecified"></Value></Payment><Payment><Reference>565434</Reference><Type>Upfront Payment</Type><Value accuracy="Payment Unspecified"></Value></Payment></PaymentsToPrincipal></PaymentsProjected><Indications><Indication id="584">Lipid metabolism disorder</Indication><Indication id="175">Hyperlipidemia</Indication></Indications><ActionsPrimary><Action id="742">Cholesterol ester transfer protein inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="2492">LDL cholesterol inhibitor</Action><Action id="71">Antihypercholesterolemic agent</Action><Action id="2491">HDL cholesterol enhancer</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology><Technology id="585">Oral formulation</Technology></Technologies><DateStart>2004-10-20T00:00:00Z</DateStart><DateEnd>2012-05-07T00:00:00Z</DateEnd><DateEventMostRecent>2012-05-07T00:00:00Z</DateEventMostRecent><Drugs><Drug id="23893"><DrugNameDisplay>dalcetrapib</DrugNameDisplay><PhaseHighestStart id="C2">Phase 2 Clinical</PhaseHighestStart><PhaseHighestNow id="C3">Phase 3 Clinical</PhaseHighestNow></Drug></Drugs><Summary>&lt;para&gt;In October 2004, &lt;ulink linkType="Company" linkID="19446"&gt;Roche&lt;/ulink&gt;   obtained  an exclusive worldwide rights, excluding Japan and South Korea for the development and commercialization of &lt;ulink linkType="Company" linkID="17327"&gt;Japan Tobacco&lt;/ulink&gt;'s &lt;ulink linkType="Drug" linkID="23893"&gt;JTT-705&lt;/ulink&gt; [&lt;ulink linkType="Reference" linkID="565434"&gt;565434&lt;/ulink&gt;]. In May 2012, Roche decided to stop developing the drug due to "a lack of clinically meaningful efficacy", as such the deal was presumed to be discontinued [&lt;ulink linkType="Reference" linkID="1288154"&gt;1288154&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1288156"&gt;1288156&lt;/ulink&gt;].&lt;/para&gt;</Summary><TimeLine><Event><Date>2004-10-20T00:00:00Z</Date><Drugs><DrugLink id="23893" nameDisplay="dalcetrapib"></DrugLink></Drugs><PaymentsToPrincipal><Payment><Reference id="565434">565434</Reference><Type>Upfront Payment</Type><Value><Accuracy sortorder="2">Payment Unspecified</Accuracy></Value></Payment></PaymentsToPrincipal><Stage id="C2">Phase 2 Clinical</Stage><Summary>&lt;para&gt;In October 2004, &lt;ulink linkType="Company" linkID="19446"&gt;Roche&lt;/ulink&gt;   obtained  an exclusive worldwide rights, excluding Japan and South Korea for the development and commercialization of &lt;ulink linkType="Company" linkID="17327"&gt;Japan Tobacco&lt;/ulink&gt;'s &lt;ulink linkType="Drug" linkID="23893"&gt;JTT-705&lt;/ulink&gt; [&lt;ulink linkType="Reference" linkID="565434"&gt;565434&lt;/ulink&gt;]. Japan Tobacco would receive an upfront  payment  and was to receive milestone payments plus royalties [&lt;ulink linkType="Reference" linkID="565434"&gt;565434&lt;/ulink&gt;].&lt;/para&gt;</Summary><Type>Original Deal</Type></Event><Event><Date>2012-05-07T00:00:00Z</Date><Drugs><DrugLink id="23893" nameDisplay="dalcetrapib"></DrugLink></Drugs><Summary>&lt;para&gt;In May 2012, Roche decided to stop developing the drug due to "a lack of clinically meaningful efficacy", as such the deal was presumed to be discontinued [&lt;ulink linkType="Reference" linkID="1288154"&gt;1288154&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1288156"&gt;1288156&lt;/ulink&gt;].&lt;/para&gt;</Summary><Type>Deal Terminated</Type></Event></TimeLine><CrossReferences><SourceEntity id="23893" type="Drug"><TargetEntity id="291317" type="siDrug">Dalcetrapib</TargetEntity></SourceEntity><SourceEntity id="19446" type="Company"><TargetEntity id="4295890594" type="organizationId">Roche Holding AG</TargetEntity></SourceEntity><SourceEntity id="17327" type="Company"><TargetEntity id="4295879109" type="organizationId">Japan Tobacco Inc</TargetEntity></SourceEntity><SourceEntity id="175" type="ciIndication"><TargetEntity id="10062060" type="MEDDRA"></TargetEntity><TargetEntity id="D006949" type="MeSH"></TargetEntity><TargetEntity id="-1908196798" type="omicsDisease"></TargetEntity><TargetEntity id="971" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="584" type="ciIndication"><TargetEntity id="10061227" type="MEDDRA"></TargetEntity><TargetEntity id="D052439" type="MeSH"></TargetEntity><TargetEntity id="-386237446" type="omicsDisease"></TargetEntity><TargetEntity id="2898" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="742" type="Action"><TargetEntity id="920" type="Mechanism">Cholesteryl Ester Transfer Protein (CETP) Inhibitors</TargetEntity><TargetEntity id="4631" type="Mechanism">Anti-CETP (Cholesteryl Ester Transfer Protein (CETP))</TargetEntity></SourceEntity><SourceEntity id="71" type="Action"><TargetEntity id="693" type="Mechanism">Cholesterol Absorption Inhibitors</TargetEntity></SourceEntity><SourceEntity id="2491" type="Action"><TargetEntity id="699" type="Mechanism">HDL-Cholesterol Increasing Agents</TargetEntity></SourceEntity></CrossReferences></Deal></ns2:com.thomsonreuters.ls.service.contract.soap.deals.v2.DealRecordsOutput>